Clinical Trial

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 29, 2025 (before its estimated January 29, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007. iQ-007 may be indicated for use in patients with Focal Seizures and Drug-resistant Epilepsy (DRE).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-21; most recent amendment 2025-12-25.
Status change: Recruiting → Active, Not Recruiting 2025-12-25
Status change: Not Yet Recruiting → Recruiting 2025-09-01
Trial Details
NCT Number NCT06899230
Lead Sponsor iQure Australia Pty Ltd
Collaborators: Avance Clinical Pty Ltd.
Conditions Drug Resistant Epilepsy, Focal Seizure
Enrollment 72 participants
Start Date 2025-04-08
Primary Completion 2026-01-29 (estimated)
Study Completion 2026-01-29 (estimated)
Updated on ClinicalTrials.gov 2025-12-29